ICER’s cost-effectiveness analysis doesn’t wholly depict
the value of new Alzheimer’s medications.
ICER released its draft evidence report on beta-amyloid antibodies for early Alzheimer’s disease.
Alzheimer’s disease and other forms of dementia have long impacted families
and communities across the country. Today, about 6 million Americans live
with Alzheimer’s disease — a number that will more than double by 2050.
Comments on ICER’s Draft Evidence Report on Plinabulin and Trilaciclib Chemotherapy-Induced Neutropenia
ICER has announced its intent to issue a final evidence report in this review without first holding a public hearing, a highly unusual decision.
ICER’s priorities differ from severe asthma patients’, and the economists’ approach could make it harder for patients to access the treatment they need. View Infographic
Just as asthma impacts people differently, existing treatment options serve some patients better than others.
Alzheimer’s and dementia already afflict too many people, yet their prevalence is expected to more than double in the coming decades. Effective Alzheimer’s treatments will reduce the disease’s economic costs today and will significantly decrease the expected cost burdens of the disease in the future. Read Comments
The Institute for Clinical and Economic Review claims that the first disease-modifying treatment for Alzheimer’s disease isn’t worth its cost.
An efficacious treatment that reduces the symptoms and risk factors associated with obstructive hypertrophic cardiomyopathy delivers great value to patients. Analyses that fail to consider all of the potential benefits, particularly the quality-of-life and productivity benefits, will undervalue this drug. Read the Letter
The Institute for Clinical and Economic Review claims that new medications for high cholesterol aren’t worth their cost. The economists overlook the needs of high-risk patients – and underestimate the impact of high cholesterol. View Graphic